Aldeyra Therapeutics (ALDX) News Today $2.92 +0.14 (+4.86%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period 161,926 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Purchased by Millennium Management LLCMillennium Management LLC bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 161,926 shares of the biotechnology company's stoJune 7, 2025 | marketbeat.comAldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | businesswire.comD. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)D. E. Shaw & Co. Inc. lessened its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 43.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 188,583 shares of the biotechnology company's stoMay 26, 2025 | marketbeat.comQ3 Earnings Forecast for ALDX Issued By Leerink PartnrsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research note issued to investors on Monday, May 19th. Leerink Partnrs analyst M. Goodman now anticipates that tMay 24, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for ALDX EarningsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities research analysts at HC Wainwright increased their Q2 2025 EPS estimates for Aldeyra Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will post earniMay 23, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Raised to "Sell" at StockNews.comStockNews.com raised shares of Aldeyra Therapeutics to a "sell" rating in a research note on Wednesday.May 23, 2025 | marketbeat.comHC Wainwright Has Strong Estimate for ALDX FY2029 EarningsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Investment analysts at HC Wainwright increased their FY2029 earnings estimates for shares of Aldeyra Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology compaMay 22, 2025 | marketbeat.comAldeyra Therapeutics' (ALDX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday.May 21, 2025 | marketbeat.comAldeyra Therapeutics Inc.May 17, 2025 | barrons.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP raised its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 21.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 735,763 shares of the biotechnology company's stock afterMay 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDXMay 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXMay 12, 2025 | prnewswire.comALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)May 7, 2025 | globenewswire.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanMay 6, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXMay 6, 2025 | prnewswire.comInvesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Invesco Ltd. decreased its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 95.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,906 shares of the bioMay 6, 2025 | marketbeat.comAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of ReproxalapMay 5, 2025 | finance.yahoo.comAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA ResubmissionMay 5, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXMay 5, 2025 | globenewswire.comShort Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Grows By 21.4%Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 4,310,000 shares, a growth of 21.4% from the March 31st total of 3,550,000 shares. Currently, 7.9% of the company's shares are sold short. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is presently 2.9 days.May 5, 2025 | marketbeat.comALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, Inc.? Contact BFA Law about Securities Investigation (NASDAQ:ALDX)May 5, 2025 | globenewswire.comALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations — Contact BFA LawMay 4, 2025 | morningstar.com683 Capital Management LLC Purchases Shares of 290,000 Aldeyra Therapeutics, Inc (NASDAQ:ALDX)683 Capital Management LLC purchased a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 290,000 shares of the biotechnology company's stock, valued at approximately $1,447,000. 683May 4, 2025 | marketbeat.comALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA LawMay 3, 2025 | globenewswire.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanMay 1, 2025 | globenewswire.comALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the CompanyMay 1, 2025 | globenewswire.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanApril 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 29, 2025 | globenewswire.comALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law FirmApril 29, 2025 | prnewswire.comALDX ALERT: Aldeyra Therapeutics (NASDAQ:ALDX) Investors are Reminded of Pending Securities Investigation – Contact BFA LawApril 29, 2025 | globenewswire.comRaymond James Financial Inc. Makes New $3.63 Million Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Raymond James Financial Inc. acquired a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 727,118 shaApril 29, 2025 | marketbeat.comBragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the FirmApril 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 28, 2025 | prnewswire.comALDX SHAREHOLDER REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about Securities InvestigationApril 28, 2025 | markets.businessinsider.comALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA LawApril 27, 2025 | globenewswire.comALDX SHAREHOLDER ALERT: BFA Law Reminds Aldeyra Therapeutics, Inc. Investors of the Continuing Securities InvestigationApril 26, 2025 | markets.businessinsider.comAldeyra Therapeutics (ALDX) to Release Quarterly Earnings on ThursdayAldeyra Therapeutics (NASDAQ:ALDX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-aldeyra-therapeutics-inc-stock/)April 26, 2025 | marketbeat.comRosen Law Firm Encourages Aldeyra Therapeutics, Inc. ...April 25, 2025 | gurufocus.comRosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDXApril 25, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 25, 2025 | globenewswire.comALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost MoneyApril 25, 2025 | globenewswire.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanApril 24, 2025 | globenewswire.comALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law FirmApril 24, 2025 | prnewswire.comLEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending ...April 23, 2025 | gurufocus.comLEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA LawApril 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 22, 2025 | prnewswire.comBragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the FirmApril 21, 2025 | globenewswire.comALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law FirmApril 21, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 21, 2025 | globenewswire.com Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDX Media Mentions By Week ALDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALDX News Sentiment▼1.890.90▲Average Medical News Sentiment ALDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALDX Articles This Week▼13▲ALDX Articles Average Week Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCAX News Today EOLS News Today PHAT News Today CAPR News Today STOK News Today UPB News Today BCYC News Today DNTH News Today KURA News Today MRVI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALDX) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALDX Stock Free ALDX Stock Alerts